Literature DB >> 24259296

Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways.

Patrick L Raber1, Paul Thevenot, Rosa Sierra, Dorota Wyczechowska, Daniel Halle, Maria E Ramirez, Augusto C Ochoa, Matthew Fletcher, Cruz Velasco, Anna Wilk, Krzysztof Reiss, Paulo C Rodriguez.   

Abstract

The accumulation of myeloid-derived suppressor cells (MDSC) in tumor-bearing hosts is a hallmark of malignancy-associated inflammation and a major mediator for the induction of T cell suppression in cancer. MDSC can be divided phenotypically into granulocytic (G-MDSC) and monocytic (Mo-MDSC) subgroups. Several mechanisms mediate the induction of T cell anergy by MDSC; however, the specific role of these pathways in the inhibitory activity of MDSC subpopulations remains unclear. Therefore, we aimed to determine the effector mechanisms by which subsets of tumor-infiltrating MDSC block T cell function. We found that G-MDSC had a higher ability to impair proliferation and expression of effector molecules in activated T cells, as compared to Mo-MDSC. Interestingly, both MDSC subgroups inhibited T cells through nitric oxide (NO)-related pathways, but expressed different effector inhibitory mechanisms. Specifically, G-MDSC impaired T cells through the production of peroxynitrites (PNT), while Mo-MDSC suppressed by the release of NO. The production of PNT in G-MDSC depended on the expression of gp91(phox) and endothelial NO synthase (eNOS), while inducible NO synthase (iNOS) mediated the generation of NO in Mo-MDSC. Deletion of eNOS and gp91(phox) or scavenging of PNT blocked the suppressive function of G-MDSC and induced anti-tumoral effects, without altering Mo-MDSC inhibitory activity. Furthermore, NO-scavenging or iNOS knockdown prevented Mo-MDSC function, but did not affect PNT production or suppression by G-MDSC. These results suggest that MDSC subpopulations utilize independent effector mechanisms to regulate T cell function. Inhibition of these pathways is expected to specifically block MDSC subsets and overcome immune suppression in cancer.
© 2013 UICC.

Entities:  

Keywords:  MDSC; eNOS; peroxynitrites

Mesh:

Substances:

Year:  2013        PMID: 24259296      PMCID: PMC3980009          DOI: 10.1002/ijc.28622

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  45 in total

Review 1.  Induced nitric oxide synthase as a major player in the oncogenic transformation of inflamed tissue.

Authors:  Guang-Yu Yang; Sofia Taboada; Jie Liao
Journal:  Methods Mol Biol       Date:  2009

2.  Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.

Authors:  Minu K Srivastava; Pratima Sinha; Virginia K Clements; Paulo Rodriguez; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

3.  A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

Authors:  Samantha Solito; Erika Falisi; Claudia Marcela Diaz-Montero; Andrea Doni; Laura Pinton; Antonio Rosato; Samuela Francescato; Giuseppe Basso; Paola Zanovello; Georgiana Onicescu; Elizabeth Garrett-Mayer; Alberto J Montero; Vincenzo Bronte; Susanna Mandruzzato
Journal:  Blood       Date:  2011-07-06       Impact factor: 22.113

4.  CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.

Authors:  Lydia A Haile; Jaba Gamrekelashvili; Michael P Manns; Firouzeh Korangy; Tim F Greten
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

Review 5.  Myeloid derived suppressor cells in human diseases.

Authors:  Tim F Greten; Michael P Manns; Firouzeh Korangy
Journal:  Int Immunopharmacol       Date:  2011-01-13       Impact factor: 4.932

Review 6.  eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity.

Authors:  Ruslan Rafikov; Fabio V Fonseca; Sanjiv Kumar; Daniel Pardo; Charles Darragh; Shawn Elms; David Fulton; Stephen M Black
Journal:  J Endocrinol       Date:  2011-06-03       Impact factor: 4.286

7.  Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

Authors:  Ilaria Marigo; Erika Bosio; Samantha Solito; Circe Mesa; Audry Fernandez; Luigi Dolcetti; Stefano Ugel; Nada Sonda; Silvio Bicciato; Erika Falisi; Fiorella Calabrese; Giuseppe Basso; Paola Zanovello; Emanuele Cozzi; Susanna Mandruzzato; Vincenzo Bronte
Journal:  Immunity       Date:  2010-06-03       Impact factor: 31.745

8.  Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.

Authors:  Steven L Highfill; Paulo C Rodriguez; Qing Zhou; Christine A Goetz; Brent H Koehn; Rachelle Veenstra; Patricia A Taylor; Angela Panoskaltsis-Mortari; Jonathan S Serody; David H Munn; Jakub Tolar; Augusto C Ochoa; Bruce R Blazar
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

9.  Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.

Authors:  Cesar A Corzo; Matthew J Cotter; Pingyan Cheng; Fendong Cheng; Sergei Kusmartsev; Eduardo Sotomayor; Tapan Padhya; Thomas V McCaffrey; Judith C McCaffrey; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

10.  Modulation of human T-cell functions by reactive nitrogen species.

Authors:  Tihana Kasic; Piergiuseppe Colombo; Cristiana Soldani; Chiuhui M Wang; Elena Miranda; Massimo Roncalli; Vincenzo Bronte; Antonella Viola
Journal:  Eur J Immunol       Date:  2011-06-07       Impact factor: 5.532

View more
  104 in total

Review 1.  Myeloid-Derived Suppressor Cells and Their Potential Application in Transplantation.

Authors:  Joseph R Scalea; Young Suk Lee; Eduardo Davila; Jonathan S Bromberg
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

Review 2.  The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies.

Authors:  Haoqing Shi; Xiangjie Qi; Bin Ma; Yanwei Cao; Lina Wang; Lijiang Sun; Haitao Niu
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

3.  Isolation of myeloid-derived suppressor cells subsets from spleens of orthotopic liver cancer-bearing mice by fluorescent-activated and magnetic-activated cell sorting: similarities and differences.

Authors:  Yaping Xu; Wenxiu Zhao; Duan Wu; Jianfeng Xu; Suqiong Lin; Kai Tang; Zhenyu Yin; Xiaomin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 4.  Energy metabolic pathways control the fate and function of myeloid immune cells.

Authors:  Amir A Al-Khami; Paulo C Rodriguez; Augusto C Ochoa
Journal:  J Leukoc Biol       Date:  2017-05-17       Impact factor: 4.962

5.  Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.

Authors:  Shan Feng; Xi Cheng; Lin Zhang; Xuemin Lu; Seema Chaudhary; Ruifang Teng; Christian Frederickson; Matthew M Champion; Ren Zhao; Liang Cheng; Yiyi Gong; Haiteng Deng; Xin Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-19       Impact factor: 11.205

6.  Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.

Authors:  Katherine A Murphy; Britnie R James; Yue Guan; Donald S Torry; Andrew Wilber; Thomas S Griffith
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.

Authors:  Andrew Stiff; Prashant Trikha; Bethany Mundy-Bosse; Elizabeth McMichael; Thomas A Mace; Brooke Benner; Kari Kendra; Amanda Campbell; Shalini Gautam; David Abood; Ian Landi; Vincent Hsu; Megan Duggan; Robert Wesolowski; Matthew Old; John Harrison Howard; Lianbo Yu; Nancy Stasik; Thomas Olencki; Natarajan Muthusamy; Susheela Tridandapani; John C Byrd; Michael Caligiuri; William E Carson
Journal:  Clin Cancer Res       Date:  2018-01-23       Impact factor: 12.531

8.  l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells.

Authors:  Matthew Fletcher; Maria E Ramirez; Rosa A Sierra; Patrick Raber; Paul Thevenot; Amir A Al-Khami; Dulfary Sanchez-Pino; Claudia Hernandez; Dorota D Wyczechowska; Augusto C Ochoa; Paulo C Rodriguez
Journal:  Cancer Res       Date:  2014-11-18       Impact factor: 12.701

9.  The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.

Authors:  Eslam Mohamed; Rosa A Sierra; Jimena Trillo-Tinoco; Yu Cao; Patrick Innamarato; Kyle K Payne; Alvaro de Mingo Pulido; Jessica Mandula; Shuzhong Zhang; Paul Thevenot; Subir Biswas; Sarah K Abdalla; Tara Lee Costich; Kay Hänggi; Carmen M Anadon; Elsa R Flores; Eric B Haura; Shikhar Mehrotra; Shari Pilon-Thomas; Brian Ruffell; David H Munn; Juan R Cubillos-Ruiz; Jose R Conejo-Garcia; Paulo C Rodriguez
Journal:  Immunity       Date:  2020-04-14       Impact factor: 31.745

10.  Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance.

Authors:  Rosa A Sierra; Jimena Trillo-Tinoco; Eslam Mohamed; Lolie Yu; Bhagelu R Achyut; Ali Arbab; Jennifer W Bradford; Barbara A Osborne; Lucio Miele; Paulo C Rodriguez
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.